Patents by Inventor Markus Hörer

Markus Hörer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260117255
    Abstract: Two-plasmid systems, helper plasmids, and/or vector plasmids for producing recombinant AAV (rAAV) vectors are described. Methods using, or uses of, the two-plasmid systems, helper plasmids and/or vector plasmids of the invention are further described.
    Type: Application
    Filed: November 6, 2025
    Publication date: April 30, 2026
    Applicant: Ascend Advanced Therapies Limited
    Inventors: Markus Hörer, Florian Sonntag, Renée Kober
  • Patent number: 12123027
    Abstract: The invention generally concerns the production of defective Adenovirus helper viruses for producing a recombinant adeno-associated virus (rAAV), wherein the Adenovirus helper virus contains at least one mutation selected from (a) an inactivating mutation in the transcription unit coding for the L4-100K protein; (b) an inactivating mutation in the transcription unit coding for the L1-52/55K protein; (c) an inactivating mutation in the transcription unit coding for the preterminal protein (pTP); (d) a mutation in the L4-100K protein in order to render it temperature-sensitive (ts); (e) a mutation in the hexon protein in order to render it temperature-sensitive (ts); and/or (f) a mutation in the L4-00K protein and a mutation in the hexon protein in order to render it temperature-sensitive (ts).
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 22, 2024
    Assignee: Ascend Advanced Therapies Limited
    Inventors: Markus Hörer, Stefan Kochanek, Caroline Hauser, Alexandra Krüger-Haag
  • Publication number: 20230323387
    Abstract: The present invention relates to helper plasmids and two-plasmid systems for producing recombinant AAV (rAAV) vectors. The invention further relates to methods of using, or uses of the helper plasmids and two-plasmid systems of the invention. The present invention also relates to a helper plasmid which does not comprise a cap gene encoding a functional set of Cap proteins and which does comprise at least one rep gene and at least one helper virus gene.
    Type: Application
    Filed: October 12, 2021
    Publication date: October 12, 2023
    Inventors: Florian Sonntag, Andreas Schulze, Bettina Finkbeiner, Markus Hörer
  • Publication number: 20220162642
    Abstract: The present invention relates to two-plasmid systems, helper plasmids, and/or vector plasmids for producing recombinant AAV (rAAV) vectors. The invention further relates to methods using, or uses of, the two-plasmid systems, helper plasmids and/or vector plasmids of the invention.
    Type: Application
    Filed: April 14, 2020
    Publication date: May 26, 2022
    Inventors: Markus HÖRER, Florian SONNTAG, Renée KOBER
  • Publication number: 20200239859
    Abstract: The invention generally concerns the production of defective Adenovirus helper viruses for producing a recombinant adeno-associated virus (rAAV), wherein the Adenovirus helper virus contains at least one mutation selected from (a) an inactivating mutation in the transcription unit coding for the L4-100K protein; (b) an inactivating mutation in the transcription unit coding for the L1-52/55K protein; (c) an inactivating mutation in the transcription unit coding for the preterminal protein (pTP); (d) a mutation in the L4-100K protein in order to render it temperature-sensitive (ts); (e) a mutation in the hexon protein in order to render it temperature-sensitive (ts); and/or (f) a mutation in the L4-00K protein and a mutation in the hexon protein in order to render it temperature-sensitive (ts).
    Type: Application
    Filed: October 12, 2018
    Publication date: July 30, 2020
    Inventors: Markus HÖRER, Stefan KOCHANEK, Caroline HAUSER, Alexandra KRÜGER-HAAG
  • Patent number: 6846665
    Abstract: The present invention relates to a method for producing a recombinant adeno-associated virus (rAAV), in which at different times a helper construct and also a vector construct are introduced into a suitable cell, and preferably the helper construct does not comprise, in particular with the exception of the AAV promoters, any nucleic acid sequences to which at least a Rep protein can essentially specifically bind and preferably the vector construct comprises ITR sequences in flop orientation. The recombinant adeno-associated viruses produced according to the method of the invention are suitable in particular for producing a tumor cell into which additionally nucleic acids coding for GM-CSF and B7.2 has been introduced, which in turn can be used in the form of a medicament for the treatment of cancers.
    Type: Grant
    Filed: February 10, 2000
    Date of Patent: January 25, 2005
    Assignee: MediGene Aktiengesellschaft
    Inventors: Markus Hörer, Michael Hallek
  • Patent number: 6838272
    Abstract: The invention relates to a process for separating viruses of different sizes, with the virus-containing solution preferably being filtered through one or more filter membranes.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: January 4, 2005
    Assignee: Switch Biotech AG
    Inventors: Christoph Bogedain, Gerhard Maass, Markus Hörer
  • Patent number: 6479273
    Abstract: The invention relates to a process for separating viruses of different sizes, with the virus-containing solution preferably being filtered through one or more filter membranes.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: November 12, 2002
    Assignee: MediGene Aktiengesellschaft
    Inventors: Christoph Bogedain, Gerhard Maass, Markus Hörer